Compare ASRV & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | CYPH |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | 298 | 6 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.9M | 73.4M |
| IPO Year | 1994 | N/A |
| Metric | ASRV | CYPH |
|---|---|---|
| Price | $3.66 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 3.2M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $0.50 |
| 52 Week High | $4.04 | $3.70 |
| Indicator | ASRV | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 66.63 |
| Support Level | $3.62 | $0.86 |
| Resistance Level | $3.96 | $1.31 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 25.00 | 77.75 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.